Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.53 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.49 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453175 | 0.92 | CFTR (0.54) | CFTRKCNH2TNIKMEN1KMT2A | |
| SCHEMBL5447192 | 0.90 | CFTR (0.52) | CFTRKCNH2TNIKMEN1KMT2A | |
| SCHEMBL5453424 | 0.89 | CFTR (0.59) | CFTRKCNH2MEN1KMT2ANPC1 | |
| SCHEMBL5458242 | 0.87 | CFTR (0.59) | CFTRKCNH2TNIKMEN1KMT2A | |
| SCHEMBL5465704 | 0.87 | NPC1 (0.51) | CFTRKCNH2TNIKMEN1KMT2A | |
| SCHEMBL5448626 | 0.87 | CFTR (0.56) | CFTRKCNH2TNIKMEN1KMT2A | |
| SCHEMBL5449304 | 0.86 | CFTR (0.65) | CFTRKCNH2TNIKMEN1KMT2A | |
| SCHEMBL5457809 | 0.85 | MEN1 (0.55) | CFTRKCNH2TNIKMEN1KMT2A | |
| SCHEMBL16962264 | 0.84 | KCNH2 (0.68) | CFTRKCNH2MEN1KMT2ANPC1 | |
| SCHEMBL5446177 | 0.84 | CFTR (0.60) | CFTRKCNH2TNIKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | CFTR 2030/4885KCNH2 3409/4885TNIK 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.